4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9 Kemurnian > 98,5% (HPLC) Lenvatinib Mesylate Intermediate Factory
Pasokan Kimia Ruifu Lenvatinib Mesylate Intermediates Kanthi Kemurnian Dhuwur
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea CAS 796848-79-8
Metil 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Metil 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene)-2,2-Dimetil-1,3-Dioxane-4,6-Dione CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4
Jeneng Kimia | 4-Chloro-7-Methoxyquinoline-6-Carboxamide |
sinonim | 4-Chloro-7-Methoxy-6-Quinolinecarboxamide;Lenvatinib Impurity 12;Lenvatinib Impurity B;Lenvatinib Impurity LFS-B |
Nomer CAS | 417721-36-9 |
Nomer CAT | RF-PI1971 |
Status Simpenan | Ing Simpenan, Kapasitas Produksi 50MT / Taun |
Formula Molekul | C11H9ClN2O2 |
Bobot Molekul | 236.65 |
Titik Lebur | > 205 ℃ (Desember) |
Kapadhetan | 1,380±0,060 g/cm3 |
Merk | Kimia Ruifu |
Item | Spesifikasi |
Penampilan | Bubuk Putih nganti Kuning Cahya |
Kemurnian / Metode Analisis | > 98,5% (HPLC) |
Mundhut ing Pangatusan | <0,50% |
Sisa ing Ignition | <0,50% |
Total Impurities | <1,50% |
Proton NMR Spectrum | Conforms kanggo Struktur |
Test Standar | Standar Perusahaan |
Panggunaan | Penengah saka Lenvatinib Mesylate (CAS: 857890-39-2) |
Paket: Botol, tas Aluminium foil, 25kg / Karton Drum, utawa miturut kabutuhan pelanggan
Kondisi panyimpenan:Simpen ing wadhah sing disegel ing papan sing adhem lan garing;Nglindhungi saka cahya lan Kelembapan
4-Chloro-7-Methoxyquinoline-6-Carboxamide (CAS: 417721-36-9) utamane digunakake minangka perantara Lenvatinib Mesylate (CAS: 857890-39-2).Dikembangake dening Eisai Inc., lenvatinib mesylate minangka inhibitor reseptor faktor pertumbuhan endothelial vaskular (VEGF) sing nduweni aktivitas nglawan subtipe VEGF 1, 2, lan 3 lan disetujoni dening FDA ing taun 2015 kanggo perawatan kanker tiroid sing beda-beda sing ana sacara lokal. ambalan, metastatik, utawa progresif lan ora nanggepi perawatan yodium radioaktif.Ing Mei 2016, FDA nyetujoni obat kasebut minangka terapi kombinasi karo everolimus kanggo perawatan karsinoma sel ginjel lanjut.Amarga VEGF (lan reseptor faktor pertumbuhan fibroblast, sing dikenal minangka FGFRs) dianggep nduweni peran ing jalur sinyal kardiovaskular, inhibisi VEGF2R lan FGFR dianggep minangka mekanisme ing mburi efek samping utama lenvatinib mesylate, yaiku hipertensi.